First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, James W. Mier et al.|Cancer Discovery|2017Cited by 418
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trialAssuntina G. Sacco, Ezra E.W. Cohen, Ruifeng Chen et al.|The Lancet Oncology|2021Cited by 257
Tipifarnib in Head and Neck Squamous Cell Carcinoma With<i>HRAS</i>MutationsAlan L. Ho, Antonio Gualberto, Irene Braña et al.|Journal of Clinical Oncology|2021Cited by 196
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and NeckRobert I. Haddad, Deborah Jean Lee Wong, Jérôme Fayette et al.|JAMA|2025Cited by 42